Clinical trial · Observational
Clinical Study of 18F-FAPI-RGD in Ovarian Cancer
Clinical Study of 18F Labeled Probe Targeting Fibroblast Activation Protein Inhibitor and Integrin Avβ3 (FAPI-RGD) in Ovarian Cancer,comparison with 18F-FDG
NCT06614062CI-TRIAL-00081101completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to learn about the value of 18F-FAPI-RGD PET/CT imaging in ovarian cancer. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination and compare it with 18F-FDG PET/CT imaging.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Observational | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Correlation between clincal indicater and PET/CT results
- timeFrame
- 2 months
- description
- Correlation of ultrasound, CT, tumor markers and 18F-FAPI-RGD PET/CT results。
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:• Age 18 and above• Patients who have been diagnosed with, or are clinically highly suspected of, Ovarian cancer and have had no other treatment within 3 months - Exclusion Criteria:• Patients with a second primary tumor• Pregnant or breastfeeding• Severe liver or kidney disease•Claustrophobia or other PET/CT scan contraindications \-
References
Publications (0)
Data not yet available
No reference posted for this study.